01316nas a2200337   4500000000100000008004100001260001600042653001000058653002900068653001600097653002900113653002800142653001200170653003100182653002100213653001100234653002000245653001200265653001500277653002500292100001400317700001800331700001200349700001200361245007900373856008200452300001000534490000600544520041400550022001400964       1971                            d  c1971 Nov 2710aAdult10aAnti-Inflammatory Agents10aBody Weight10aClinical Trials as Topic10aCosts and Cost Analysis10aDapsone10aDrug Resistance, Microbial10aErythema Nodosum10aHumans10aInfant, Newborn10aleprosy10aPhenazines10aPhysical Examination1 aKarat A B1 aJeevaratnam A1 aKarat S1 aRao P S00aControlled clinical trial of clofazimine in untreated lepromatous leprosy.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1799776/pdf/brmedj02677-0020.pdf  a514-60 v43 a<p>A comparison of clofazimine and dapsone in the management of untreated lepromatous leprosy showed no significant differences between the two drugs in terms of morphological and bacterial indices. The incidence of erythema nodosum leprosum was similar in the two groups. Since dapsone is cheaper than clofazimine it remains the drug of choice for the routine management of untreated lepromatous leprosy.</p>  a0007-1447